Pridopidine Sales Forecast

Key Factors Driving Pridopidine Growth

Clinical Evidence Suggesting Disease-Modifying Effects in Huntington’s Disease

• Results from the Phase III PROOF-HD trial — published in Nature Medicine — showed that pridopidine slowed clinical progression and maintained function, cognition, and motor performance in a predefined subgroup of HD patients who were not taking antidopaminergic medicines (ADMs).
• These data represent the first Phase III evidence of clinically meaningful slowing of disease progression across multiple domains in HD with a favorable safety profile.

Expansion Into Pivotal Phase III Programs in ALS

The US FDA has cleared the start of a pivotal Phase III trial (PREVAiLS) for ALS, enrolling ~500 patients globally, planned to begin in early 2026.

PREVAiLS is designed to confirm encouraging subgroup signals from the Phase II HEALEY ALS Platform trial showing slowing of disease progression, improvement in respiratory function, bulbar and speech measures, and a survival benefit in early, rapidly progressive ALS.

Strategic Commercial Partnerships

Prilenia signed a collaboration and license agreement with Ferrer for the commercialization and co-development of pridopidine in Europe and select international markets, with a total deal value of ~€500 million (~US$550 million) including upfront, milestone, and royalty payments.

Broad and Established Safety Database

Pridopidine’s clinical development program has involved more than ~1,600 people with safety data extending up to ~7 years, showing a favorable tolerability profile in placebo-controlled studies and long-term exposures.

Regulatory Incentives and Orphan Designations

Pridopidine holds Orphan Drug designation in both the US and the EU for HD and ALS, and Fast Track designation by the FDA for HD.

Orphan status can lead to market exclusivity and development incentives, while Fast Track facilitates frequent interactions with regulators and potential priority review if data support approval.

Pridopidine Recent Developments

• In October 2025, Prilenia Therapeutics B.V. and Ferrer announced the presentation of five posters outlining slowing of clinical progression and additional pridopidine data at the 2025 HSG HD Clinical Research Congress.

“Pridopidine Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Pridopidine for potential indication like Amyotrophic lateral sclerosis and Parkinson’s disease in the 7MM. A detailed picture of Pridopidine’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Pridopidine for potential indications. The Pridopidine market report provides insights about Pridopidine’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Pridopidine performance, future market assessments inclusive of the Pridopidine market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Pridopidine sales forecasts, along with factors driving its market.

Pridopidine Drug Summary

Pridopidine is an investigational, orally bioavailable small-molecule agonist of the sigma-1 receptor (S1R) developed by Prilenia Therapeutics, primarily targeting Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS) by modulating cellular stress responses at the mitochondria-associated endoplasmic reticulum membrane. It selectively activates S1R to enhance mitochondrial function, reduce endoplasmic reticulum stress, promote protein clearance, upregulate neurotrophic factors like BDNF, restore synaptic plasticity, and inhibit neuroinflammation, with secondary state-dependent effects on dopamine D2 receptors that normalize cortico-striatal signaling without inducing psychosis. In Phase III trials (e.g., PROOF-HD for early manifest HD), it showed safety and trends in motor/cognitive benefits in subgroups despite missing primary endpoints, alongside promising ALS data; administered at 45 mg BID, common side effects include mild gastrointestinal issues and fatigue. The report provides Pridopidine’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Pridopidine Market Report

The report provides insights into:

• • A comprehensive product overview including the Pridopidine MoA, description, dosage and administration, research and development activities in potential indication like Amyotrophic lateral sclerosis and Parkinson’s disease.
• • Elaborated details on Pridopidine regulatory milestones and other development activities have been provided in Pridopidine market report.
• • The report also highlights Pridopidine‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• • The Pridopidine market report also covers the patents information, generic entry and impact on cost cut.
• • The Pridopidine market report contains current and forecasted Pridopidine sales for potential indications till 2034.
• • Comprehensive coverage of the late-stage emerging therapies for respective indications.
• • The Pridopidine market report also features the SWOT analysis with analyst views for Pridopidine in potential indications.

Methodology

The Pridopidine market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Pridopidine Analytical Perspective by DelveInsight

In-depth Pridopidine Market Assessment

This Pridopidine sales market forecast report provides a detailed market assessment of Pridopidine for potential indication like Amyotrophic lateral sclerosis and Parkinson’s disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Pridopidine sales data uptil 2034.

Pridopidine Clinical Assessment

The Pridopidine market report provides the clinical trials information of Pridopidine for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Pridopidine Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Pridopidine Market Potential & Revenue Forecast

• Projected market size for the Pridopidine and its key indications
• Estimated Pridopidine sales potential (Pridopidine peak sales forecasts)
• Pridopidine Pricing strategies and reimbursement landscape

Pridopidine Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Pridopidine Market positioning compared to existing treatments
• Pridopidine Strengths & weaknesses relative to competitors

Pridopidine Regulatory & Commercial Milestones

• Pridopidine Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Pridopidine Clinical Differentiation

• Pridopidine Efficacy & safety advantages over existing drugs
• Pridopidine Unique selling points

Pridopidine Market Report Highlights

• • In the coming years, the Pridopidine market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• • The Pridopidine companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Pridopidine’s dominance.
• • Other emerging products for Amyotrophic lateral sclerosis and Parkinson’s disease are expected to give tough market competition to Pridopidine and launch of late-stage emerging therapies in the near future will significantly impact the market.
• • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Pridopidine in potential indications.
• • Analyse Pridopidine cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• • Our in-depth analysis of the forecasted Pridopidine sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Pridopidine in potential indications.

Key Questions

• • What is the class of therapy, route of administration and mechanism of action of Pridopidine? How strong is Pridopidine’s clinical and commercial performance?
• • What is Pridopidine’s clinical trial status in each individual indications such as Amyotrophic lateral sclerosis and Parkinson’s disease and study completion date?
• • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Pridopidine Manufacturers?
• • What are the key designations that have been granted to Pridopidine for potential indications? How are they going to impact Pridopidine’s penetration in various geographies?
• • What is the current and forecasted Pridopidine market scenario for potential indications? What are the key assumptions behind the forecast?
• • What are the current and forecasted sales of Pridopidine in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• • What are the other emerging products available and how are these giving competition to Pridopidine for potential indications?
• • Which are the late-stage emerging therapies under development for the treatment of potential indications?
• ·       How cost-effective is Pridopidine? What is the duration of therapy and what are the geographical variations in cost per patient?